Lunan Pharmaceutical launches 3 drugs and 1 first imitation

On May 25, Lunan Pharmaceutical issued a press release stating that axitinib tablets, tenofovir disoproxil fumarate, and lipoic acid injection developed by Shandong New Times Pharmaceutical Co.

About Axitinib

According to the press release, the approval number of axitinib tablets (specification: 5mg): National Medicine Zhunzi H20213406, is the first domestic company to be approved under the new category 4, which is deemed to have passed the consistency evaluation.

Axitinib is a small molecule tyrosine kinase inhibitor (TKI).

Studies have shown that at therapeutic doses, axitinib can inhibit tyrosine kinase receptors, including vascular endothelial growth factor receptors VEGFR-1, VEGFR-2 and VEGFR-3.

About Tenofovir Disoproxil fumarate

Tenofovir disoproxil fumarate was developed by Gilead of the United States.

The drug was approved in the United States in 2001 for use in combination with other antiretroviral drugs to treat HIV-1 infection; in 2008, it was approved in the United States for the treatment of chronic hepatitis B (HBV), and the dosage forms are tablets and oral powders.

AIDS virus (HIV) is a virus that infects cells of the human immune system.

Hepatitis B virus (hepatitis B for short) is a disease caused by hepatitis B virus (HBV) infecting the body.

About lipoic acid injection

The original manufacturer of lipoic acid injection was the German Stadt Pharmaceutical Factory.

Diabetic peripheral neuropathy (DPN) is one of the most common chronic complications of diabetes.